• 1
    Larsson SC, Kumlin M, Ingelman-Sundberg M, Wolk A. Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr 2004; 79: 93545.
  • 2
    Astorg P. Dietary N-6 and N-3 polyunsaturated fatty acids and prostate cancer risk: a review of epidemiological and experimental evidence. Cancer Causes Control 2004; 15: 36786.
  • 3
    Simopoulos A, Cleland L. Omega-6/omega-3 essential fatty acid ratio: the scientific evidence. Basel: Karger AG; 2003.
  • 4
    Terry PD, Rohan TE, Wolk A. Intakes of fish and marine fatty acids and the risks of cancers of the breast and prostate and of other hormone-related cancers: a review of the epidemiologic evidence. Am J Clin Nutr 2003; 77: 53243.
  • 5
    Terry PD, Terry JB, Rohan TE. Long-chain (n-3) fatty acid intake and risk of cancers of the breast and the prostate: recent epidemiological studies, biological mechanisms, and directions for future research. J Nutr 2004; 134: S341220.
  • 6
    Kirschenbaum A, Klausner AP, Lee R, Unger P, Yao S, Liu XH, Levine AC. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology 2000; 56: 6716.
  • 7
    Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000; 42: 738.
  • 8
    Lee LM, Pan CC, Cheng CJ, Chi CW, Liu TY. Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. Anticancer Res 2001; 21: 12914.
  • 9
    Mahmud S, Franco E, Aprikian A. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer 2004; 90: 939.
  • 10
    Shahedi K, Lindstrom S, Zheng SL, Wiklund F, Adolfsson J, Sun J, Augustsson-Balter K, Chang BL, Adami HO, Liu W, Gronberg H, Xu J. Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int J Cancer 2006; 119: 66872.
  • 11
    Hedelin M, Klint A, Chang ET, Bellocco R, Johansson JE, Andersson SO, Heinonen SM, Adlercreutz H, Adami HO, Gronberg H, Balter KA. Dietary phytoestrogen, serum enterolactone and risk of prostate cancer: the cancer prostate sweden study (sweden). Cancer Causes Control 2006; 17: 16980.
  • 12
    National Prostate Cancer Registry.
  • 13
    Sandblom G, Dufmats M, Olsson M, Varenhorst E. Validity of a population-based cancer register in Sweden–an assessment of data reproducibility in the South-East Region Prostate Cancer Register. Scand J Urol Nephrol 2003; 37: 11219.
  • 14
    Sobin LH, Wittenkind CH. TNM classification of malignant tumours, 6th edn. New York: Wiley, 2002.
  • 15
    Chang ET, Hedelin M, Adami HO, Gronberg H, Balter KA. Alcohol drinking and risk of localized versus advanced and sporadic versus familial prostate cancer in Sweden. Cancer Causes Control 2005; 16: 27584.
  • 16
    Chang ET, Smedby KE, Zhang SM, Hjalgrim H, Melbye M, Ost A, Glimelius B, Wolk A, Adami HO. Dietary factors and risk of non-hodgkin lymphoma in men and women. Cancer Epidemiol Biomarkers Prev 2005; 14: 51220.
  • 17
    Administration NF., vol. 2005.
  • 18
    dbSNP N., vol. 2005.
  • 19
    SNPer., vol. 2005.
  • 20
    Willet W. Nutritional epidemiology, 2nd edn. New York: Oxford University Press, 1998.
  • 21
    McGee D, Reed D, Yano K. The results of logistic analyses when the variables are highly correlated: an empirical example using diet and CHD incidence. J Chronic Dis 1984; 37: 71319.
  • 22
    Hosmer DW, Lemeshow S. Applied logistic regressioned. New York: Wiley, 1989.
  • 23
    Leitzmann MF, Stampfer MJ, Michaud DS, Augustsson K, Colditz GC, Willett WC, Giovannucci EL. Dietary intake of n-3 and n-6 fatty acids and the risk of prostate cancer. Am J Clin Nutr 2004; 80: 20416.
  • 24
    Yang YJ, Lee SH, Hong SJ, Chung BC. Comparison of fatty acid profiles in the serum of patients with prostate cancer and benign prostatic hyperplasia. Clin Biochem 1999; 32: 4059.
  • 25
    Mamalakis G, Kafatos A, Kalogeropoulos N, Andrikopoulos N, Daskalopulos G, Kranidis A. Prostate cancer vs. hyperplasia: relationships with prostatic and adipose tissue fatty acid composition. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 46777.
  • 26
    Terry P, Lichtenstein P, Feychting M, Ahlbom A, Wolk A. Fatty fish consumption and risk of prostate cancer. Lancet 2001; 357: 17646.
  • 27
    Welch AA, Lund E, Amiano P, Dorronsoro M, Brustad M, Kumle M, Rodriguez M, Lasheras C, Janzon L, Jansson J, Luben R, Spencer EA et al. Variability of fish consumption within the 10 European countries participating in the European Investigation into Cancer and Nutrition (EPIC) study. Public Health Nutr 2002; 5: 127385.
  • 28
    Augustsson K, Michaud DS, Rimm EB, Leitzmann MF, Stampfer MJ, Willett WC, Giovannucci E. A prospective study of intake of fish and marine fatty acids and prostate cancer. Cancer Epidemiol Biomarkers Prev 2003; 12: 647.
  • 29
    Hursting SD, Thornquist M, Henderson MM. Types of dietary fat and the incidence of cancer at five sites. Prev Med 1990; 19: 24253.
  • 30
    Rose DP, Connolly JM. Omega-3 fatty acids as cancer chemopreventive agents. Pharmacol Ther 1999; 83: 21744.
  • 31
    Siezen CL, van Leeuwen AI, Kram NR, Luken ME, van Kranen HJ, Kampman E. Colorectal adenoma risk is modified by the interplay between polymorphisms in arachidonic acid pathway genes and fish consumption. Carcinogenesis 2005; 26: 44957.
  • 32
    Aronson WJ, Glaspy JA, Reddy ST, Reese D, Heber D, Bagga D. Modulation of omega-3/omega-6 polyunsaturated ratios with dietary fish oils in men with prostate cancer. Urology 2001; 58: 2838.
  • 33
    Fritsche E, Baek SJ, King LM, Zeldin DC, Eling TE, Bell DA. Functional characterization of cyclooxygenase-2 polymorphisms. J Pharmacol Exp Ther 2001; 299: 46876.
  • 34
    Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, Nelson WG. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 2005; 26: 117081.
  • 35
    Zheng SL, Augustsson-Balter K, Chang B, Hedelin M, Li L, Adami HO, Bensen J, Li G, Johnasson JE, Turner AR, Adams TS, Meyers DA et al. Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the Cancer Prostate in Sweden Study. Cancer Res 2004; 64: 291822.
  • 36
    Sun J, Wiklund F, Zheng SL, Chang B, Balter K, Li L, Johansson JE, Li G, Adami HO, Liu W, Tolin A, Turner AR et al. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J Natl Cancer Inst 2005; 97: 52532.
  • 37
    Chaudry A, McClinton S, Moffat LE, Wahle KW. Essential fatty acid distribution in the plasma and tissue phospholipids of patients with benign and malignant prostatic disease. Br J Cancer 1991; 64: 115760.
  • 38
    Kirschenbaum A, Liu X, Yao S, Levine AC. The role of cyclooxygenase-2 in prostate cancer. Urology 2001; 58: 12731.
  • 39
    Culp BR, Titus BG, Lands WE. Inhibition of prostaglandin biosynthesis by eicosapentaenoic acid. Prostaglandins Med 1979; 3: 26978.